1. Tirzepatide was superior to placebo with regard to changes in HbA1c, serum glucose, body weight loss, and proportion of patients achieving HbA1c targets of less than 7.0%.
2. Compared to placebo, the proportion of adverse events with tirzepatide were mildly elevated.
Evidence Rating Level: 1 (Excellent)
Study Rundown: In many patients...